The therapeutic potential of a novel, targeted-release formulation of oral budesonide
(Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase …

Background IgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …

Background IgA nephropathy is thought to be associated with mucosal immune system
dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage …

It is more than 50 years since the first description of IgA nephropathy (IgAN) by the Parisian
pathologist, Jean Berger. 1 Over this time, IgAN became recognized as the most common …

Targeting the alternative complement pathway is an attractive therapeutic strategy given its
role in the pathogenesis of immunoglobulin A nephropathy (IgAN). Iptacopan (LNP023) is …

Background. Systemic corticosteroid treatment has been shown to exert some protection
against renal deterioration in IgA nephropathy (IgAN) but is not commonly recommended for …

Methods This randomized, double-blind, dose-ranging, parallel-group adaptive design
Phase 2 study (NCT03373461) enrolled patients with biopsy-confirmed IgAN (within the …

The pivotal event in the pathophysiology of IgA nephropathy is the binding of circulating IgA-
containing immune complexes to mesangial cells, with secondary glomerular and …

Introduction Targeting the alternative complement pathway (AP) is an attractive therapeutic
strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology …

IgA nephropathy (IgAN) is the most common type of glomerulonephritis in Asia and the
Western world. In most patients, it follows an asymptomatic to oligosymptomatic course and …